AdaptHealth

AHCONASDAQUSD

THESIS ALERT

Email me when the AHCO thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$7.80
+$0.08 (+1.04%)Today 1M +28.71%
After hours$7.800.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$7.72
Prior regular-session close from the quote source.
$7.64–$7.93
Regular-session low and high so far today.
2.2M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Feb 23 projected
Projected for 2027-02-23 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$5.21–$13.43
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own AHCO if reimbursement and execution stop eroding margins.

AHCO price history

Latest price$7.80Today+$0.08 (+1.04%)
AHCO +27.35%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

INVESTMENT THESIS

What must happen next

5 MATERIAL PROPOSITIONS
  • AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels.HoldingMateriality: High

    GAAP annual revenue remained large and relatively stable at $3.20 billion in FY2023, $3.26 billion in FY2024, and $3.24 billion in FY2025. If the referral platform holds share, revenue stability gives management time to fix margins; if it loses relevance, cost cuts cannot protect the equity.

    Watch: Major Medicare Advantage payors such as UnitedHealth or Humana steer more patients to captive, preferred, or lower-cost suppliers.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue remained large and relatively stable at $3.20 billion in FY2023, $3.26 billion in FY2024, and $3.24 billion.

    Open source ↗
  • AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing.WeakeningMateriality: High

    GAAP annual gross profit was $624.1 million in FY2023 and $681.1 million in FY2024 before weakening in FY2025. Gross profit is the first test of whether AdaptHealth has pricing and cost power or is simply passing volume through at weaker economics.

    Watch: CMS, state Medicaid programs, or Medicare Advantage plans reduce reimbursement schedules or increase prior-authorization friction.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual gross profit was $624.1 million in FY2023 and $681.1 million in FY2024 before weakening in FY2025.

    Open source ↗
  • The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator.HoldingMateriality: Medium

    GAAP annual operating income recovered from a loss of $598.4 million in FY2023 to income of $263.7 million in FY2024. Operating leverage determines whether revenue stability becomes equity value or is consumed by overhead and execution costs.

    Watch: Branch consolidation, billing automation, or workflow standardization fails to reduce labor and administrative cost per order.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income recovered from a loss of $598.4 million in FY2023 to income of $263.7 million in FY2024.

    Open source ↗
  • AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair.StrengtheningMateriality: Medium

    GAAP annual operating cash flow increased from $373.9 million in FY2022 to $480.7 million in FY2023, $541.8 million in FY2024, and $601.8 million in FY2025. Sustained cash conversion is the main reason the equity can survive margin volatility and leverage; if collections deteriorate, the turnaround becomes much riskier.

    Watch: Medicare Advantage payors increase claim denials, audits, or prior authorizations, delaying or reducing collections.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow increased from $373.9 million in FY2022 to $480.7 million in FY2023, $541.8 million in FY2024.

    Open source ↗
  • Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock.StrengtheningMateriality: Medium

    Total liabilities declined from $3.06 billion at FY2022 year-end to $3.04 billion at FY2023 year-end, $2.91 billion at FY2024 year-end, and $2.79 billion at FY2025 year-end. If liabilities keep falling, more cash flow can accrue to shareholders; if leverage rises or refinancing tightens, creditors capture much of the business value.

    Watch: Management resumes debt-funded acquisitions before demonstrating durable margin recovery.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total liabilities declined from $3.06 billion at FY2022 year-end to $3.04 billion at FY2023 year-end, $2.91 billion at FY2024 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels. If the referral platform holds share, revenue stability gives management time to fix margins; if it loses relevance, cost cuts cannot protect the equity.

AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing. Gross profit is the first test of whether AdaptHealth has pricing and cost power or is simply passing volume through at weaker economics.

The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator. Operating leverage determines whether revenue stability becomes equity value or is consumed by overhead and execution costs.

AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair. Sustained cash conversion is the main reason the equity can survive margin volatility and leverage; if collections deteriorate, the turnaround becomes much riskier.

Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock. If liabilities keep falling, more cash flow can accrue to shareholders; if leverage rises or refinancing tightens, creditors capture much of the business value.

All standing thesis claims
Original report summary

reimbursement and execution stop eroding margins.

Evidence assessed Nov 3, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for AdaptHealth

Where the evidence on AdaptHealth disagrees: Mixed on the latest evidence (Nov 3, 2026). Of its 5 thesis points, 2 strengthening, 2 holding and 1 weakening.

Bull case: what the evidence supports

  • AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels.

    sec.gov ↗

  • The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator.

    sec.gov ↗

  • AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair.

    sec.gov ↗

  • Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock.

    sec.gov ↗

Bear case: what the evidence questions

  • AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · AdaptHealth

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

Loading the break-condition record for AdaptHealth.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.

RISKS / FALSIFIERS

What could break the thesis

  • Major Medicare Advantage payors such as UnitedHealth or Humana steer more patients to captive, preferred, or lower-cost suppliers.
  • CMS, state Medicaid programs, or Medicare Advantage plans reduce reimbursement schedules or increase prior-authorization friction.
  • Branch consolidation, billing automation, or workflow standardization fails to reduce labor and administrative cost per order.
  • Medicare Advantage payors increase claim denials, audits, or prior authorizations, delaying or reducing collections.
  • Management resumes debt-funded acquisitions before demonstrating durable margin recovery.

AHCO news

Loading headlines…

FINANCIAL STATEMENTS

AHCO income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

AHCO: quick answers

When does AdaptHealth (AHCO) report earnings next?
AdaptHealth's next results are projected for February 23, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
What is AHCO's short interest?
As of October 30, 2026, 10.9M AHCO shares were sold short, 8.00% of its shares outstanding, up 6.8% from the count before. At the stock's average daily volume that is 5.2 days to cover. FINRA publishes the count twice a month. AHCO short interest history
Have members of Congress traded AHCO?
Reports made public in the last 90 days disclose 2 trades in AHCO by 1 filer: 1 purchase and 1 sale. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed AHCO trade
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.